Quantcast

Latest Interferon beta-1a Stories

2011-03-02 01:25:00

ROCKLAND, Mass., March 2, 2011 - EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) on the new drug application (NDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing-remitting multiple sclerosis (MS). (Logo: http://photos.prnewswire.com/prnh/20101126/SF07905LOGO-b) A complete response...

2011-02-10 06:00:00

ROCKLAND, Mass., Feb. 10, 2011 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced the opening of a state-of-the-art research center in Billerica, MA, establishing it as a "hub" within the Merck KGaA research organization. Representing a $65 million investment, the Billerica research facility supports the company's commitment to developing and discovering innovative treatments in oncology, neurodegenerative diseases and infertility. Nearly 100...

2010-12-17 07:30:00

NEW YORK, Dec. 17, 2010 /PRNewswire-FirstCall/ -- A study published this week by ITG (NYSE: ITG) revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year. Gilenya came onto the market in late September as the first FDA-approved oral disease-modifying MS drug, and Novartis initially faced safety concerns and monitoring requirements that...

2010-12-06 07:00:00

EXTON, Pa., Dec. 6, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that surveyed neurologists indicate that their initial trial of Novartis's Gilenya has been hampered by potential safety / tolerability concerns and monitoring requirements. The majority of surveyed neurologists indicate they are aware of Gilenya and -- even with already high levels of familiarity -- they remain interested in learning more about the product. As the first oral disease-modifying agent (DMA) to be...

2010-11-26 01:18:00

ROCKLAND, Mass., Nov. 26, 2010 /PRNewswire/ -- EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today that the U.S. Food and Drug Administration (FDA) has extended its review period for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS) by three months to February 28, 2011. The FDA granted Priority Review status for Cladribine Tablets in July of 2010, reducing the standard 10-month review period to six months, which was set to end on...

2010-11-02 08:13:00

EXTON, Pa., Nov. 2, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. has released a syndicated report focused on the management and treatment of multiple sclerosis (MS) in the US. ChartTrends®: Multiple Sclerosis is an annual publication based on patient level data collected on 1,000 MS patients being treated with disease modifying agents (DMAs). In addition to helping to define the DMA-treated MS patient (demographics, co-morbidities, concomitant medications,...

2010-09-22 00:30:00

EAST HANOVER, N.J., Sept. 22 /PRNewswire/ -- Today Novartis announced that the US Food and Drug Administration (FDA) approved the oral multiple sclerosis (MS) treatment Gilenya(TM) (fingolimod) 0.5 mg daily, a first-line treatment for relapsing forms of multiple sclerosis - the most common forms of the disease. The FDA approval makes Gilenya the first oral treatment indicated for relapsing forms of MS available in the US. To view the multimedia assets associated with this release,...

2010-09-21 14:08:00

Recipients voted highest-scoring medical journal ads by over 4,600 MDs MOUNT LAUREL, N.J., Sept. 21 /PRNewswire-USNewswire/ -- The Association of Medical Media (AMM) presented The Doctors' Choice Awards to the highest-scoring medical journal advertisements Thursday, September 16, 2010. The Doctors' Choice Awards, an annual study developed by AMM, researches physician attitudes toward product advertising through web-based surveying of 325 advertisements in 21 specialties from the 86 most...

2010-09-01 07:00:00

ROCKLAND, Mass. and NEW YORK, Sept. 1 /PRNewswire-FirstCall/ -- EMD Serono, Inc. and Pfizer Inc. (NYSE: PFE) announced today that MS LifeLines, an educational and support service which includes a call center, has achieved a milestone in servicing one million in-bound calls since its inception in 2002. MS LifeLines is sponsored by EMD Serono, Inc. an affiliate of Merck KGaA, Darmstadt, Germany, and Pfizer Inc. The service is available to the multiple sclerosis (MS) community, including...

2010-07-28 02:38:00

ROCKLAND, Mass., July 28 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS). The application also has been granted a Priority Review designation by the FDA, which means the review period for the NDA is reduced. The goal for completing a Priority Review is six...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related